Evogene Reports Financial Results for the Third Quarter and First Nine Months of 2026, Highlighting Progress in Two Internal Development Programs
<p>Company advances its internally developed drug discovery program targeting acute graft-versus-host disease (aGVHD) and AgPlenus' fungicide discovery programs targeting novel MoA against Septoria REHOVOT, Israel, Nov. 19, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a...</p>
Read original article ↗